Amgen Sets Aside $780M for Whistleblower, Kickback Suits

Advertisement

Biotech company Amgen, based in Thousand Oaks, Calif., has set aside $780 million to cover the costs of settling federal and state probes into its sales and marketing practices, according to a Bloomberg report.

Read more at Becker’s ASC Review.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.